New treatment for generalized vitiligo using JAK inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy of baricitinib, a systemic JAK inhibitor, in treating active generalized vitiligo, a skin disorder characterized by depigmented patches. The study aims to assess the treatment's ability to promote repigmentation and improve the quality of life for patients affected by this condition. Participants will receive oral mini pulses of baricitinib along with Narrow Band UVB treatment, while those with specific exclusion criteria will be omitted to ensure accurate evaluation of the treatment's effects. The trial will monitor the safety and effectiveness of this novel approach in a controlled setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* active generalized vitiligo patients with body surface area involved \>5% excluding hands and feet
* no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks.

Exclusion Criteria:

* acrofacial, acral, segmental or mucosal vitiligo
* patients on another immunosuppressive agent
* patients have other skin conditions (psoriasis, SLE, alopecia areata) that would interfere with evaluations of the effect of study medication on vitiligo.
* patients who suffered from systemic diseases affecting S100B (e.g. Subarachnoid hemorrhage, Alzheimer disease and inflammatory diseases) or from other dermatological diseases affecting S100B level (e.g. malignant melanoma)
* Patients immunocompromised, uncontrolled arterial hypertension, clinically serious viral, bacterial, fungal, or parasitic infection, anemia, history of thromboembolic event, cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, lymphoproliferative disease, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness.
* Pregnancy and lactation.

Where it's running

• Qena university hospital, Qena faculty of medicine
  Qina, Egypt Recruiting

Study contacts

• Principal investigator: EMAN A OSMAN, bachelor — Qena university hospital, Qena faculty of medicine
• Study coordinator: Eman A Osman, bachelor
• Email: em.ea01127@gmail.com
• Phone: +20 1127052748

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Baricitinib for persistent low platelets after stem cell transplant

  We’re testing baricitinib to see if it can help people with long-term low platelets after an allogeneic stem cell transplant who didn’t respond to other treatments.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07535645

• Telitacicept plus baricitinib for refractory rheumatoid arthritis

  This test tries combining telitacicept with baricitinib to see if it helps adults with refractory rheumatoid arthritis who haven't improved on other treatments.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07491016

• Baricitinib Added to Corticosteroids in PMR (Polymyalgia Rheumatica) May Improve Control

  This study tests whether baricitinib plus low-dose steroids works better than steroids alone for people 50 and older with PMR.

  Recruiting at 19 sites Phase 3 University Hospital, Brest · Aix-en-Provence and 22 other locations · NCT07279688

• Baricitinib for people with STAT3‑related Hyper‑IgE (Job) syndrome who have lupus-like disease or atopic dermatitis

  This trial will test whether the JAK inhibitor baricitinib can be taken safely and may reduce lupus-like symptoms or severe eczema in people aged 12 and older with STAT3-related Hyper‑IgE (Job) syndrome.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07262983

• Baricitinib to preserve insulin-producing beta cells in people newly diagnosed with type 1 diabetes

  This trial will test whether the drug baricitinib can help preserve insulin-producing beta cells in children and adults who were recently diagnosed with type 1 diabetes.

  Recruiting at 108 sites Phase 3 Eli Lilly and Company · Aurora, Colorado and 129 other locations · NCT07222332

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.